A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol. 2012;30(28):3439–3443.
   PubMed Web of Science ®Google Scholar
• Davies A. Double-hit lymphoma: so what? Hematol Oncol. 2019;37(Suppl. 1):19–23.
   PubMedGoogle Scholar
• Abramson JS. Hitting back at lymphoma: how do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment? Cancer. 2019;125(18):3111–3120.
   PubMed Web of Science ®Google Scholar
• Li S, Desai P, Lin P, et al. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology. 2016;68(7):1090–1098.
   PubMed Web of Science ®Google Scholar
• Zeng D, Desai A, Yan F, et al. Challenges and opportunities for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement (double-hit lymphoma). Am J Clin Oncol. 2019;42(3):304–316.
   PubMed Web of Science ®Google Scholar
• Ok CY, Medeiros LJ. High-grade B-cell lymphoma: a term re-purposed in the revised WHO Classification. Pathology. 2020;52(1):68–77.
   PubMed Web of Science ®Google Scholar
• Kim A, Stevenson P, Cassaday RD, et al. Impact of double- or triple-hit pathology on rates and durability of radiation therapy response among patients with relapsed or refractory large B-cell lymphoma. Pract Radiat Oncol. 2020;10(1):44–52.
   PubMed Web of Science ®Google Scholar
• Laude MC, Lebras L, Sesques P, et al. First‐line treatment of double‐and triple‐hit lymphomas: survival and tolerance data from a Retrospective Multicenter French Study. Am J Hematol. 2021;96(3):302–311.
   PubMed Web of Science ®Google Scholar
• Al-Juhaishi T, Mckay J, Sindel A, et al. Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020;21(6):653–661.
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017;31(2):37–42.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. How I treat double-hit lymphoma. Blood. 2017;130(5):590–596.
   PubMed Web of Science ®Google Scholar
• Huang J-J, Xia Y, Wang Y, et al. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution. Oncotarget. 2016;7(27):41242–41250.
   PubMedGoogle Scholar
• Ma Z, Niu J, Cao Y, et al. Clinical significance of 'double-hit’ and 'double-expression’ lymphomas. J Clin Pathol. 2020;73(3):126–138.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617.
   PubMed Web of Science ®Google Scholar
• Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118(17):4173–4183.
   PubMed Web of Science ®Google Scholar
• Alsharif R, Dunleavy K. Burkitt lymphoma and other high-grade B-cell lymphomas with or without MYC, BCL2, and/or BCL6 rearrangements. Hematol Oncol Clin North Am. 2019;33(4):587–596.
   PubMed Web of Science ®Google Scholar
• Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–514.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ. Advancing the management of double hit lymphoma. Oncotarget. 2017;8(45):78245–78246.
   PubMedGoogle Scholar
• Friedberg JW. Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges. Chin Clin Oncol. 2015;4(1):9.
   PubMedGoogle Scholar
• Zhang HW, Chen ZW, Wang LY, et al. Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma. Zhonghua Zhong Liu Za Zhi. 2016;38(3):206–210.
   PubMedGoogle Scholar
• Petrich AM, Nabhan C, Smith SM. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer. 2014;120(24):3884–3895.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
   PubMed Web of Science ®Google Scholar
• Ohmoto A, Fuji S. Double-hit and double-expressor B-cell lymphomas: current treatment strategies and impact of hematopoietic cell transplantation. Adv Cell Gene Ther. 2018;1(2):e13.
   Google Scholar
• Scott DW, King RL, Staiger AM, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;131(18):2060–2064.
   PubMed Web of Science ®Google Scholar
• Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145–156.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Ayers EC, Bond DA, et al. Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Br J Haematol. 2020;189(2):313–317.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017;35(20):2260–2267.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Tsui A, Wall M, et al. Current challenges and novel treatment strategies in double hit lymphomas. Ther Adv Hematol. 2016;7(1):52–64.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Mato AR. Emerging strategies in treating double hit lymphomas. Clin Lymphoma Myeloma Leuk. 2017;17(9):563–568.
   PubMed Web of Science ®Google Scholar
• Abramson JS. The spectrum of double hit lymphomas. Hematol Oncol Clin North Am. 2016;30(6):1239–1249.
   PubMed Web of Science ®Google Scholar
• Davies A. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently? Hematology Am Soc Hematol Educ Program. 2017;2017(1):284–294.
   PubMed Web of Science ®Google Scholar
• Dunleavy K. Optimal management of double-hit lymphoma. J Oncol Pract. 2016;12(3):241–242.
   PubMed Web of Science ®Google Scholar
• Phuoc V, Sandoval-Sus J, Chavez JC. Drug therapy for double-hit lymphoma. Drugs Context. 2019;8:1–13.
   Google Scholar
• Merron B, Davies A. Double hit lymphoma: how do we define it and how do we treat it? Best Pract Res Clin Haematol. 2018;31(3):233–240.
   PubMed Web of Science ®Google Scholar
• Reagan PM, Davies A. Current treatment of double hit and double expressor lymphoma. Hematology Am Soc Hematol Educ Program. 2017;2017(1):295–297.
   PubMedGoogle Scholar
• Li LR, Wang L, He YZ, et al. Current perspectives on the treatment of double hit lymphoma. Expert Rev Hematol. 2019;12(7):507–514.
   PubMed Web of Science ®Google Scholar
• TRIAL PI. Venetoclax boosts benefits of R-EPOCH in aggressive B-cell lymphomas; 2020.
   Google Scholar
• Medicine NUNLo. Testing the addition of a new anti-cancer drug, venetoclax, to usual chemotherapy for high grade B-cell lymphomas, Bethesda, MD. Available from: https://clinicaltrials.gov/ct2/show/NCT03984448
   Google Scholar
• Godfrey JK, Nabhan C, Karrison T, et al. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019;125(11):1830–1836.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Ruppert AS, Giri S, et al. Randomized phase II/III study of DA-EPOCH-R+/–venetoclax in previously untreated double hit lymphoma: initial results from alliance A051701. Blood. 2021;138(Suppl. 1):523.
   Google Scholar
• Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN guidelines insights: B-cell lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650–661.
   PubMed Web of Science ®Google Scholar
• Goyal G, Caponetti GC, Silberstein PT. Double-hit lymphoma. J Clin Exp Hematop. 2015;55(1):51–53.
   PubMedGoogle Scholar
• Huang S, Nong L, Wang W, et al. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. Diagn Pathol. 2019;14(1):81.
   PubMedGoogle Scholar
• Uchida A, Isobe Y, Asano J, et al. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-protein expression" lymphoma with MYC and BCL2 rearrangements. Haematologica. 2019;104(7):1417–1421.
   PubMed Web of Science ®Google Scholar
• Bisso A, Sabo A, Amati B. MYC in germinal center-derived lymphomas: mechanisms and therapeutic opportunities. Immunol Rev. 2019;288(1):178–197.
   PubMed Web of Science ®Google Scholar
• NCI. Randomized phase II/III study of venetoclax (ABT199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double expressing lymphomas [clinical trial webpage]; 2019 [cited 2020 Jan 28]; NCT03984448. Available from: https://clinicaltrials.gov/ct2/show/NCT03984448
   Google Scholar
• Azizian NG, Liu Y, Pham LV, et al. Rational targeted therapeutics for double-hit lymphoma. Int J Hematol Oncol. 2019;8(3):IJH19.
   PubMedGoogle Scholar
• Li W, Gupta SK, Han W, et al. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.
   PubMedGoogle Scholar
• Di Rocco A, De Angelis F, Ansuinelli M, et al. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? Expert Rev Hematol. 2017;10(9):761–774.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685–2693.
   PubMed Web of Science ®Google Scholar
• Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582–1587.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Wright GW, Phelan JD, Coulibaly ZA, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568.e14.
   PubMed Web of Science ®Google Scholar